

July 14, 2023

Notice of Refunds to Covered Entities Q1 2022 - Q3 2023

Amring Pharmaceuticals Inc. has recently recalculated 340B Ceiling Prices for the NDCs listed below for the periods of Q1 2022 – Q3 2023. The recalculated Ceiling Prices are the result of restatements of Medicaid pricing data that were submitted to the Centers for Medicare & Medicaid Services.

Amring Pharmaceuticals Inc. has asked the Health Resources and Services Administration (HRSA) to post this notice on the HRSA public website to ensure transparency to all 340B Covered Entities.

As a result of the recalculated 340B Ceiling Prices, Amring Pharmaceuticals Inc. has determined that a refund may be owed to 340B Covered Entities that purchased the below products during the period of Q1 2022 – Q3 2023.

NDC	Product Family
69918010101	Desmopressin 0.1 mg
69918020101	Desmopressin 0.2 mg
69918030130	Tranexamic Acid 650mg
69918050105	Desmopressin Nsl Spry
69918056030	Mesalamine 1000mg
69918070010	Succinylcholine Chloride
69918070025	Succinylcholine Chloride
69918070026	Succinylcholine Chloride
69918072002	Arsenic Trioxide
69918072010	Arsenic Trioxide
69918073110	Isoproterenol HCI Injection
69918073510	Isoproterenol HCI Injection
69918089910	Desmopressin 1 ml
69918090110	Desmopressin 10 ml

Amring Pharmaceuticals Inc. will use wholesaler chargeback records to calculate and automatically issue refund adjustments through the wholesalers that submitted the original sale on behalf of the 340B Covered Entities. If a Covered Entity believes they have not received an appropriate adjustment, please contact Amring Pharmaceuticals Inc. via email at <a href="mailto:amringfinance@amringpharma.com">amringfinance@amringpharma.com</a> with a subject line of "340B Standard Refile" and your entities 340B ID. In addition, please provide Quantity, Original Purchase Invoice Number, Invoice Date, and the Wholesaler the product was purchased through in the body of your email so that we can research your inquiry further.